Reenie McCarthy, CEO speaks for Stealth Biotherapeutics during the Innovative Showcase at [email protected] 2019. REGISTER for our next ophthalmology conference today http://bit.ly/2yFA6cv.
Reenie McCarthy, CEO, explains that Stealth is focused on mitochondrial dysfunction. They have programs in late stage rare genetic mitochondrial diseases, a program in phase 2b for dry AMD, and a robust pipeline, with the first asset moving into the clinic later in 2019. Stealth’s lead compound is elamipretide, which binds preferentially to cardiolipin, an important structural compound of the inner mitochondrial membrane essential for mitochondrial function. Mitochnodrial dysfunction can lead to cardiolipin peroxidation. This leads to a breakdown of the inner membrane, and more oxidative stress. In a mouse model elamipretide normalizes mitochondrial morphology. AMD is characterized by mitochondrial dysfunction so it’s a good functional target for a drug that targets mitochondrial function. A Phase 1 trial showed improvement in multiple parameters of visual function, and a Phase 2b trial is currently enrolling, which focuses on geographic atrophy. It has a primary endpoint of low light visual acuity, which has been approved by the FDA. The company expects to have data from the study early in 2021.
This presentation takes place at [email protected] at the Ritz-Carlton in Chicago on July 25, 2019.
Download the presentation here: https://ois.net/wp-content/uploads/2019/07/Stealth-Biotherapeutics-FINAL-7-17-2019.pdf
FOLLOW Ophthalmology Innovation Summit On Social Media:
► Facebook: https://facebook.com/ois.net
► Twitter: https://twitter.com/oistweets
JOIN Our Group For Ophthalmology Innovation & Investment On LinkedIn
SUBSCRIBE To Our Weekly OIS Newsletter
VIEW Our Past Ophthalmology Event Conferences:
REGISTER For Our Next Conference:
#OIS #Ophthalmology #Healthcare
Ophthalmology Innovation Summit, or OIS for short, facilitates meaningful interactions and the exchange of information between clinical, capital, and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs.
The Ophthalmology Innovation Summit programs are presented annually by Healthegy, Inc. as affiliate meetings with American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), Southeastern Congress of Optometry (SECO), and American Society of Retina Specialists (ASRS).
Healthegy also is the producer of Aesthetics Innovation Summit (AIS), which unites the clinical, corporate and capital leaders to facilitate the exchange of insights on emerging trends while showcasing exciting new drugs, devices, and technologies for the aesthetics market which is projected to double by 2025.
► Website: https://attendais.com
► Facebook: https://facebook.com/AestheticsInnovationSummit
► Instagram: https://instagram.com/AIS_Summit
► Twitter: https://twitter.com/AIS_Summit
► Healthegy Website: https://healthegy.com